Five things for pharma marketers to know:
- BrainStorm Therapeutics said it is withdrawing its Biologics License Application and conducting a Phase IIIb clinical trial for its amyotrophic lateral sclerosis treatment NurOwn.
- Eli Lilly agreed to acquire another antibody-drug conjugate biotech, swooping in for France-based Mablink Bioscience, according to media reports.
- Intellia Therapeutics said the FDA cleared its Investigational New Drug application for its gene editing drug.
- SeaStar Medical shares rose sharply after the medical-device company won a third FDA breakthrough-device designation for its Selective Cytopheretic Device.
- Philanthropies with large stakes in weight-loss drugmakers Eli Lilly and Novo Nordisk have surged in value and are now among the biggest in the world.
